Focus Financial Network Inc. Buys 10,616 Shares of Boston Scientific Corporation $BSX

Focus Financial Network Inc. grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 39.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,203 shares of the medical equipment provider’s stock after acquiring an additional 10,616 shares during the quarter. Focus Financial Network Inc.’s holdings in Boston Scientific were worth $1,588,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Boston Scientific during the 1st quarter valued at $28,000. Finally, Sfam LLC purchased a new stake in Boston Scientific during the 4th quarter valued at $29,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 1.5%

Shares of BSX stock opened at $51.19 on Wednesday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm has a fifty day moving average price of $45.87 and a 200-day moving average price of $59.97. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market cap of $74.19 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the business posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has authorized a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BSX shares. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Bank of America reduced their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Canaccord Genuity Group dropped their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday, May 28th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $71.62.

Insider Buying and Selling

In related news, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 204,322 shares of company stock worth $9,939,221. Corporate insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.